The U.S. Food and Drug Administration has accelerated the review process for bepirovirsen, a hepatitis B treatment. The drug is being developed by GSK in partnership with Ionis Pharmaceuticals.
- FDA priority review granted for bepirovirsen
- Collaboration between GSK and Ionis Pharmaceuticals